Novavax climbs after raising annual revenue forecast
06/08/2026 13:14
BUZZ-Novavax climbs after raising annual revenue forecast ** Shares of vaccine maker Novavax NVAX.O rise 2.1% to $7.86 premarket
** NVAX expects annual revenue of $235 million to $275 million compared to its previous expectation of between $230 million and $270 million
** Co's Q2 revenue of $56.7 million beats analysts' average expectation of $52.5 million, according to LSEG data
** Co says completion of manufacturing technology transfer to Sanofi is expected in mid-2027 and would trigger a $75 million milestone payment to Novavax
** Up to last close, stock up 14.6% YTD
(Reporting by Christy Santhosh)
Recent news on Novavax
See all newsNovavax shareholder Shah Capital to step back from activist role
Brief: Mabion Signs Deal With Novavax Expanding Cooperation To Analytical Services For Early-Stage Pipeline Projects
Brief: Sanofi Spokesperson Says Nuvaxovid to Be Available Across U.S. for 2026-27 Respiratory Virus Season
US FDA approves updated COVID vaccines for 2026-27 season
US STOCKS-Wall St rises as yields ease, Moderna lifts healthcare stocks